PhaseBio Pharmaceuticals Total non-current liabilities

Total non-current liabilities of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current liabilities growth rates and interactive chart.


Highlights and Quick Summary

  • Total non-current liabilities for the quarter ending June 29, 2021 was $104 Million (a 36.83% increase compared to previous quarter)
  • Year-over-year quarterly Total non-current liabilities increased by 143.94%
  • Annual Total non-current liabilities for 2020 was $60.6 Million (a 331.71% increase from previous year)
  • Annual Total non-current liabilities for 2019 was $14 Million (a 86.61% increase from previous year)
  • Annual Total non-current liabilities for 2018 was $7.52 Million (a 75.5% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current liabilities of PhaseBio Pharmaceuticals

Most recent Total non-current liabilitiesof PHAS including historical data for past 10 years.

Interactive Chart of Total non-current liabilities of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Total non-current liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $103.64 $75.74
2020 $60.6 $42.49 $26.62 $15.88 $60.6
2019 $14.04 $9.44 $10.08 $8.51 $14.04
2018 $7.52 $10.37 $7.52
2017 $4.29

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.